Lipid-Nanopartikel (LNP) in zugelassenem Impfstoff Deutschland

• 

  The Role of LNP in the Success of RNA-based Vaccines

  Thanks to their high efficacy, solid safety profile and the hope they exhibit as a framework for vaccines in the future, it has been very good at LNPs. They are good at shielding the crucial genetic information and getting it into our cells without doing any damage. In other words, Wachstumshormon 1 LNPs can be leveraged to make vaccines against a variety of diseases. The scientist will be looking to have LNPs for treating diseases like cancer, flu, and even HIV soon. It is so exciting what LNPs could do, the potential looks limitless!

• 

  Effective, Safe and Promising for Future Immunization

  Commercialisation is a big term, which in easy words refers to making use of a scientific idea into an object or medicine people can use. This way is not simple that needs time to finish many experiments and passes by health experts; Marathon: It was incredibly exciting for saRNA-LNP-Kapselungsprotokoll vaccines to go from no one being able to get them Entwicklung von gewebespezifischen RNA-LNPs. One such example is an RNA vaccine nucleated with LNPs developed in only 63 days! Thanks to the wonders of modern technology and researchers from different countries pooling their research, this rapid advancement became possible.

• 

  The Journey of LNP-based Vaccines to Commercialization

  The platform of Yanacbiotech is considered to be one of the top technologies for rapid formulation, aqueous-free composition vaccine and medicine product development in China and the company has also gained rich experience of preparation of LNP. Their main aim is to make vaccines safe, effective, and accessible to all. As demonstrated by COVID-19, they have come a long way with RNA vaccines. However, Yaohai is also working on more LNPs to develop for influenza and cancer. The reason we can believe in this world where more people can absolutely be saved from disease is because they so believe in this technology.

Why choose Yaohai Lipid Nanoparticle (LNP) in Licensed Vaccine?

• Robuste Lieferkette und Fertigungskapazitäten

  Yaohai Bio-Pharma, a Lipid Nanoparticle (LNP) in Licensed Vaccine manufacturer of biological products, is a specialist in microbial fermentations. We have built a modern factory equipped with modern facilities and strong RD and manufacturing capabilities. Five drug substance production lines that are compliant with GMP standards for microbial purification and ferment, as well as two fill and finish lines for vials as well as cartridges, as well as needles that are pre-filled, are readily available. The available fermentation scales vary from 100L to 500L, 1000L, to 2000L. Filling volumes vary from 1ml to 25ml. Syringes or cartridges pre-filled are filled with the equivalent of 1-3ml. Our cGMP-compliant production facility ensures the availability of stable clinical samples and commercial products. The big molecules that are produced at our plant are readily available for international delivery.

• Qualitätssystem und Einhaltung globaler Vorschriften

  Yaohai BioPharma, a top 10 Microbial CDMO, integrates quality and regulatory matters. We have a quality system that is fully compliant with the current GMP standards, as well as international regulations. Our team of regulatory experts has a deep understanding of world-wide regulatory frameworks. This lets us accelerate biological launches. We are able to guarantee traceable production procedures and high-quality products that conform with regulations from the US FDA, Lipid Nanoparticle (LNP) in Licensed Vaccine, Australia TGA, and China NMPA. Yaohai BioPharma has successfully passed an on-site audit conducted of the European Union's Qualified Person (QP) for our GMP quality system and production site. We also have been through the initial certification audits of the ISO9001 Quality Management System and ISO14001 Environmental Management System.

• Fachkompetenz und langjährige Erfahrung

  Yaohai Bio-Pharma is a leading microbial biologics CDMO. Our main focus has been the production of Lipid Nanoparticle (LNP) in Licensed Vaccine and therapeutics to treat pets, human and veterinary health. We have state-of-the-art RD platforms and manufacturing technology that cover the entire manufacturing process beginning with the development of microbial strains Cell banking, process and method development, through commercial and clinical manufacture that ensures the successful delivery of innovative solutions. Over time we've gained a vast knowledge of microbial-based bio processing. We have successfully completed more than 200 global projects, and help our clients with navigating the rules and regulations of the US FDA, EU EMA, Australia TGA, and China NMPA. We are able to react promptly to market demands and provide tailored CDMO services due to our experience and expertise.

• Anpassung, Effizienz und Kosteneffizienz

  Lipid Nanoparticle (LNP) in Licensed Vaccine has experience in manufacturing biologics that are that are derived from microorganisms. We provide tailored RD as well as manufacturing solutions, while minimising the risk. We have experimented with a variety of techniques, such as recombinant cellular subunits of vaccines (including peptides), growth factors, hormones and the cytokines. We have specialized in multiple microorganisms like yeast extracellular and intracellular secretion (yields up to 15g/L) and bacteria intracellular soluble and inclusion bodies (yields up to 10g/L). We also have the BSL-2 fermentation platform to develop bacterial vaccines. We are experts in improving processes, increasing product yields, and decreasing production costs. With an effective technology team, we ensure timely and quality project delivery and bring your products to market faster.

Verwandte Produktkategorien

• Analytische Methoden für Plasmid-DNA
• Herstellung des Bakteriophagen AP205 VLP
• Herstellung von Bakteriophage Q VLP
• Herstellung chimärer VLP-Impfstoffe
• Herstellung konjugierter VLP-Impfstoffe
• Herstellung von DNA-Impfstoffen
• E. coli-Fermentation zur VLP-Produktion
• Herstellung von GLP-1-Agonisten
• GLP-1 Analoge Fertigung

Finden Sie nicht, was Sie suchen?
Kontaktieren Sie unsere Berater für weitere verfügbare Produkte.